Takayasu Kurata
Kansai Medical University · 437 works · 35,444 citations · h-index 58
Top works
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins.
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- Two species of human CRK cDNA encode proteins with distinct biological activities.
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- CRK Protein Binds to Two Guanine Nucleotide-Releasing Proteins for the Ras Family and Modulates Nerve Growth Factor-Induced Activation of Ras in PC12 Cells
- Angiomyolipoma: imaging findings in lesions with minimal fat.
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
- Transgenic mice susceptible to poliovirus.
- Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- Is response rate or stable disease rate a surrogate endpoint for survival in the treatment of advanced non-small cell lung cancer using epidermal growth factor receptor tyrosine kinase inhibitors?
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- Serological and Virological Evidence of a Hantaan Virus-Related Enzootic in the United States
- Fatal encephalitis/encephalopathy in primary human herpesvirus-6 infection.